fundregtracker.
Last verified 2026-10-23

Fund News — Friday 23 October 2026

Dated edition·every item source-linked·permanent link

This edition

All editions →

Dated and permanent — an edition is never rewritten after publication; corrections land in its changelog.

The week's fund-industry signal, curated: fund launches and closes, manager and servicer moves, and figures from our own registers. Every trade-press item links its source and ends with why it matters to someone who runs or services funds. Trade-press items are published only after every cited source was machine-verified; register figures are computed from the published data files. This is a dated, permanent edition — it is not updated after publication; corrections land in the changelog.

Launches, closes and wind-downs

Ara Partners closes inaugural energy fund at its $2.5bn hard cap

Private Equity Wire · 2026-10-21

Global

Ara Partners has closed Ara Energy Fund I at its $2.5bn hard cap, made up of $1.8bn in fund commitments and more than $700m in associated co-investment capital. The cap was reached ten months after the December 2025 initial close. Commitments came from pension funds, insurers, sovereign wealth funds, endowments and foundations across North America and Europe. It is the first energy fund from the US manager, which was founded in 2017. The firm had approximately $10.6bn of assets under management at 30 June 2026. The platform was launched with HF Capital, the Haslam family's investment office. It targets conventional energy assets across power generation, renewable fuels, and fuel delivery and distribution. A seed portfolio is already assembled. It spans about 3GW of thermal generation in US power markets, and ethanol plants with annual capacity of roughly 400 million gallons. It also includes the JET retail fuel network of around 970 stations in Germany and Austria. Shameek Konar, head of Ara Energy, said rising global energy demand was creating opportunities. He said these lay in improving the capacity, resilience and operating efficiency of existing infrastructure. Threadmark acted as global placement agent, and Davis Polk acted as legal counsel.

Industry moves

Permira agrees to sell credit intelligence provider Octus to LSEG for $3.5bn in cash

Private Equity Wire · 2026-10-22

Global

Permira has agreed to sell Octus, the New York-based credit intelligence provider formerly known as Reorg, to LSEG for $3.5bn in cash, according to Bloomberg. Octus covers leveraged finance, distressed debt, restructuring and private credit, and is forecast to generate more than $300m of revenue this year. Permira agreed to invest in the business in 2022. Founder and chief executive Kent Collier will reportedly stay on after completion, which is expected in the first half of 2027. LSEG plans to fund the purchase with external debt, taking leverage towards the upper end of its 1.5 to 2.5 times target range by the end of 2027. It expects the deal to be earnings-neutral in its first full year before turning accretive. The deal follows LSEG's $27bn acquisition of Refinitiv, completed in 2021, and comes while Elliott Investment Management presses LSEG to accelerate shareholder returns and review its portfolio. LSEG reported third-quarter constant currency income growth of 8%, against guidance of up to 7.5%. It says it has capacity for an additional £1bn to £1.5bn of share buybacks in 2027.

EQT agrees €9.6bn takeover of molecular testing group Qiagen

Private Equity Wire · 2026-10-22

Europe

EQT has agreed to acquire Qiagen for €9.6bn, according to a Bloomberg report. A consortium including ADIA and CPP Investments will pay €46.50 per share in cash following approval from Qiagen's board. The price is a premium of about 40% to the share price before earlier reports of a potential takeover. The deal is described as one of the largest European healthcare buyouts this year. It reportedly follows two other major EQT acquisitions this year: the £9.3bn takeover of UK-listed Intertek and the A$9.3bn purchase of Cleanaway. Qiagen, Netherlands-incorporated with main offices in Germany, has drawn takeover interest for years. Thermo Fisher abandoned a $12bn bid in 2020 after failing to secure enough shareholder support. Qiagen later explored a combination with BioMérieux. KKR also reportedly submitted a competing offer in the latest sale process. PSquared Asset Management, one of Qiagen's largest shareholders, had publicly supported a transaction.

Vinci Compass buys Brazilian reinsurer AustralRe for about BRL336m to launch a permanent capital platform

Private Equity Wire · 2026-10-22

North America

Vinci Compass is buying Brazilian reinsurer AustralRe, which its partners founded in 2011 alongside Vinci Capital Partners, for about BRL336m, or 1.0 times tangible book value. Consideration is expected to comprise roughly BRL247m in cash and 1.7 million new Class A shares, with the final structure reportedly depending on minority shareholders' preferences. AustralRe operates across 16 Latin American countries and wrote BRL3bn of gross written premiums in the 12 months to June 2026. It holds about BRL1.8bn in cash and investments. It will anchor a new division, Vinci Permanent Capital Solutions, run separately from asset management. The division's capital will fund GP commitments, seed new strategies and support third-party fundraising. Vinci says those commitments can be particularly demanding given Latin America's longer investment cycles. The firm expects the deal to be immediately accretive to distributable earnings per share at a double-digit rate. Completion is reportedly expected in the first quarter of 2027, subject to regulatory and antitrust approvals.

CVC considers a take-private of Verisure, a year after its €13.7bn IPO

Private Equity Wire · 2026-10-22

Europe

CVC Capital Partners is considering a bid to take Verisure private, according to the Financial Times, though its interest reportedly remains preliminary and a formal offer is not certain. Hellman & Friedman floated the Swiss-headquartered home security provider in Stockholm in October 2025 at a €13.7bn valuation, and the shares now trade roughly 30% below the IPO price. H&F remains the largest shareholder with a stake of around 44%. It bought the business from EQT in 2011 for €2.3bn alongside Bain Capital, then acquired Bain's stake in 2015. Other sponsor-backed listings have also struggled, with Cinven's HBX Group falling from an IPO price of €11.50 to below €8. EQT's Galderma, by contrast, generated about $26bn in proceeds for its fund and co-investors on exit this year. Buyers have meanwhile pursued discounted listed European companies, among them KKR's £4.7bn acquisition of Spectris. Permira and CPP Investments have also agreed the £2.7bn take-private of fund services group JTC.

Changelog

Publication and corrections (1 entry) · latest 2026-10-23
  • 2026-10-23 — published.
↑ Top